Summary
Background Comparative, real-life and long-term evidence on the effectiveness and safety of phototherapy and systemic therapy in moderate-to-severe atopic eczema (AE) is limited. Such data must come from well-designed prospective patient registries. Standardization of data collection is needed for direct comparisons and data pooling. Objectives To reach a consensus on how and when to measure the previously defined domain items of the TREatment of ATopic eczema (TREAT) Registry Taskforce core dataset for research registries for paediatric and adult patients with AE. Methods Proposals for the measurement instruments were based on recommendations of the Harmonising Outcome Measures for Eczema (HOME) initiative, the existing AE database of TREATgermany, systematic reviews of the literature and expert opinions. The proposals were discussed at three face-to-face consensus meetings, one teleconference and via e-mail. The frequency of follow-up visits was determined by an expert survey. Results A total of 16 experts from seven countries participated in the 'how to measure' consensus process and 12 external experts were consulted. A consensus was reached for all domain items on how they should be measured by assigning measurement instruments. A minimum follow-up frequency of initially 4 weeks after commencing treatment, then every 3 months while on treatment and every 6 months while off treatment was defined. Conclusions This core dataset for national AE research registries will aid in the comparability and pooling of data across centres and country borders, and enables international collaboration to assess the long-term effectiveness and safety of phototherapy and systemic therapy used in patients with AE.
What's already known about this topic?
• Comparable, real-life and long-term data on the effectiveness and safety of phototherapy and systemic therapy in patients with atopic eczema (AE) are needed.
• There is a high diversity of outcomes and instruments used in AE research, which require harmonization to enhance comparability and allow data pooling.
What does this study add?
• Our taskforce has reached international consensus on how and when to measure core domain items for national AE research registries.
• This core dataset is now available for use by researchers worldwide and will aid in the collection of unified data.
What are the clinical implications of this work?
• The data collected through this core dataset will help to gain better insights into the long-term effectiveness and safety of phototherapy and systemic therapy in AE and will provide important information for clinical practice.
• Standardization of such data collection at the national level will also allow direct data comparisons and pooling across country borders (e.g. in the analysis of treatment-related adverse events that require large patient numbers).
A significant number of paediatric and adult patients with moderate-to-severe atopic eczema (AE) may require phototherapy or systemic immunomodulatory therapy at some point during their life. For adults, ciclosporin, and recently dupilumab, are currently the only systemic therapies that are approved by the European Medicines Agency, 1,2 while only dupilumab has been approved by the U.S. Food and Drug Administration. 3 For children, there are no approved systemic therapies, although our European and North American treatment surveys show that they are regularly prescribed. 4, 5 While there is some evidence on the short-term effectiveness of phototherapy and systemic immunomodulatory therapy, there is a clear lack of head-to-head comparison trials and a paucity of data on the long-term effectiveness and safety of such treatments. 6, 7 As randomized controlled trials have very strict inclusion criteria, important subgroups of patients (e.g. those with comorbidities) are commonly excluded and therefore evidence in real-life populations is missing. All of this requires data collection from well-defined patient cohorts. [8] [9] [10] To harmonize data collection for such observational cohorts, the TREatment of ATopic eczema (TREAT) Registry Taskforce initiated a consensus exercise to develop a core set of domains and domain items for AE treatment research registries. After an international Delphi study and consensus meeting, the core dataset ('what to measure') was agreed on, consisting of 19 domains with 69 corresponding domain items (49 at baseline and 20 at follow-up). 11, 12 As the next step in this consensus-finding process, we performed a consensus exercise to define how and when to measure the core domain items to harmonize data collection fully within national AE treatment research registries and prevent heterogeneity. 13, 14 Patients and methods
Study design
To establish a core set of measurement instruments ('how to measure'), three face-to-face expert consensus meetings, one teleconference and final discussions via e-mail were arranged. For this process we used the following sources to guide decision making: (i) recommendations from the Harmonising Outcome Measures for Eczema (HOME) initiative were used where possible (e.g. regarding the capture of clinical signs, patient-reported outcomes and quality of life); [15] [16] [17] (ii) relevant literature, in particular systematic reviews considering measurement instruments in AE; 7, 13, 14, [18] [19] [20] (iii) the existing AE database of TREATgermany, 21 which already included over 100 patients at the start of this study; (iv) personal communications with experts in the field of measurement instruments for specific domain items [e.g. K. McElhone (British Association of Dermatologists Biologics and Immunomodulators Register; BADBIR), personal communication]; and (v) the current use of measurement instruments in clinical practice and clinical expertise of the participants. During all meetings, feasibility and current common practice were kept in mind.
All meetings were chaired by either P.I.S. or C.F. During each session, the evidence for each suggested measurement instrument was presented in the form of a PowerPoint presentation and written handouts, followed by whole group discussions. These discussions were iterative and continued until full consensus was achieved. Voting was done by a show of hands and was therefore not anonymous. Whenever possible, validated measurement instruments were selected. If multiple validated instruments were available, decisions were based on (in order of importance): (i) HOME recommendations; (ii) quality of the validation studies; and (iii) the feasibility and, in particular, the potential to be used in different countries, and the number of available translations of the measurement instrument. In case the consensus on domain items could not be reached immediately during the meetings (e.g. due to a lack of evidence), items were assigned to participating TREAT members for further investigation, taking into account their areas of expertise. These items were then rediscussed at the next consensus meeting. The three face-to-face consensus meetings were audiorecorded for reference at the next meetings.
To define when the domain items should be measured ('when to measure'), in September 2017 we conducted an online survey among all participants using SurveyMonkey software. Options put to the vote were based on current clinical practice ( Fig. S1 ; see Supporting Information). The results of the survey were discussed and approved in a small group via e-mail.
Participants
The participants were physicians, patients and nonclinical researchers (i.e. health economists, epidemiologists/methodologists) from the TREAT Registry Taskforce with an interest in AE and/or AE measurement instruments. We also consulted external experts through personal communications (mostly e-mail) from, for example, the Coronel Institute of Occupational Health and the Medical Psychology Department of the Academic Medical Centre in Amsterdam for items considering work and health, and items considering treatment adherence.
Definition of consensus
Consensus was predefined both for the 'how to measure' and for the 'when to measure'. Consensus for the 'how to measure' was achieved when 100% of the participants present during the consensus meeting agreed on the measurement instrument. Consensus on the follow-up frequency and the visit window ('when to measure') was achieved when the majority of the participants voted for one of the options.
Results

How to measure
In March, May and June 2017 four consensus meetings were held. The first was done by teleconference and the other three were by face-to-face meetings in London, Amsterdam and Nantes. A total of 16 participants met, all members of the TREAT Registry Taskforce, including 11 academic dermatologists, one dermatology resident, one dermatology PhD student, one patient/patient representative, one epidemiologist/ methodologist, and one health economist ( Fig. S2 ; see Supporting Information). A total of 12 experts were consulted for specific items.
During the face-to-face meetings, slight alterations were made to the 'what to measure' core dataset. To make the core dataset as feasible as possible some domain items were merged with others. The items 'medical history', 'follow-up (FU) safety bloods', 'adverse events that cause stop or switch of therapy or change in dosage' and 'probability of relationship with treatment' are now captured as part of the other items (for details see Table 1 ). Additionally, the items 'other significant illnesses' and 'other medication relevant for AE treatment response' were added as they were not previously captured in the 'what to measure' core dataset. After these alterations, the final 'what to measure' core dataset consists of 70 items (50 baseline items and 20 follow-up items; Table 1 ). For all items, consensus was reached on the measurement instruments.
Details on specific domain items
Ethnicity
We reviewed all ethnicity classifications that we had access to, based on a literature search, including the one used by the U.K. Biobank, the German National Cohort and BADBIR. The classification system shown in Table 1 was made (based on all these reviewed classification systems) and was selected because this system allows patients and physicians to choose from an extensive list of ethnicities. The option to select and specify two ethnicities is given as well. To capture migration, country of birth of patient and parents were also added.
Educational status
Educational status is an important predictor of health and disease. 22 For this item, the International Standard Classification of Education (ISCED) system was chosen. The ISCED has, for instance, been adopted by the United Nations Educational, Scientific and Cultural Organization General Conference and consists of definitions that have been agreed on internationally. Further, it facilitates the comparison of education systems from different countries. The group agreed that each country would translate this classification to its national educational classification.
It was decided to record the highest completed educational level (from the parent or child in case of a child or from the patient themselves if an adult).
Use of validated diagnostic criteria
Both the quality of the gathered data and the feasibility of the registry were considered. Many lists of diagnostic criteria for For definitions on these phenotypical and morphological characteristics see Figure S3 (see Supporting Information AE are available and reviewed (e.g. the U.K. Working Party criteria, Hanifin and Rajka criteria, refined Millennium Criteria). 23 Although in clinical practice a diagnosis of AE is often made without the use of specific diagnostic criteria, nevertheless the use of validated diagnostic criteria is desirable within the context of national AE treatment research registries. During the consensus exercise, we decided to give national registries the option to decide which validated diagnostic criteria they would like to use. In addition, the option 'physician diagnosed' was added in case no diagnostic criteria were used.
Previous and current phototherapy and systemic therapy
In addition to recording the type, dose and outcome of past therapies, we also recommend to capture the number of treatment courses, the average treatment (maintenance) dose and whether adverse events associated with these treatments occurred. Where available, we also recommend recording the cumulative dose of phototherapy. It was decided to add investigational therapies to the registry (both for past and current systemic therapies), although during the initial Delphi exercise, this was voted out.
Current topical treatments
The question was whether or not to register the potency of corticosteroids as the classification differs between countries. For feasibility reasons it was therefore decided to recommend registration of the potency using the known national classification system, but this is not mandatory.
Malignancies, serious infections and other significant illnesses
While only past malignancies and past serious infections were voted in during the Delphi exercise, the knowledge of current malignancies, infections and other comorbidities provide us with important information for safety and subgroup analyses. Thus, these items were added. The item 'medical history' (tuberculosis, HIV, hepatitis B or C), which was previously voted in during the Delphi exercise, is now captured as part of the item 'past serious infections'.
Other medication relevant for an atopic eczema treatment response
Although not voted in during the 'what to measure' Delphi process, this item has been added, as such therapies (e.g. immunotherapy or aeroallergens) might need to be considered as a confounder of the response to AE treatments.
Days lost from usual activities
Some of the costs of AE are associated with decreased productivity or days lost from work. 24 Registration of the days lost from work is important to register for health technology assessment and cost-effectiveness research. However, this would bias results towards those patients in productive areas.
Hence, the name of this item was changed to 'days lost from usual activities'.
Skin examination
Treatment response might be influenced by the phenotype of AE. Therefore, we suggest to document whether certain phenotypical and morphological characteristics are present. For definitions on these characteristics see Figure S3 (see Supporting Information).
Details on the physician-and patient-reported domain items
Physician-assessed clinical signs and patient-reported symptoms
For all items, HOME recommendations were followed, that is, the Eczema Area and Severity Index was selected for the item 'physician-assessed clinical signs' 15 and the Patient-Oriented Eczema Measure (POEM) was selected for the item 'patientreported symptoms'. 16, 25, 26 
Patient-reported symptoms
At the fifth meeting of HOME (HOME V) it was agreed that the inclusion of intensity of itch should be investigated, as the POEM only measures frequency of itch. 17 Schoch et al. and Phan et al. found that the 11-point numerical rating scale (NRS) for itch has good reliability and validity and that recall bias increases with the recall period. 18, 27 The 11-point (NRS) was therefore added to the item 'patient-reported symptoms' and after consultation with external experts it was decided to register the peak itch for the previous 24 h. 28 
Reporting of disease control
For this item, which is analogous to the long-term control domain as defined by HOME, HOME V has recommended the use of repeated measurements of the long-term control subdomains: clinical signs, symptoms, quality of life and a patient global instrument. 17 
Investigator/Physician Global Assessment
Futamura et al. concluded that global assessments are often used in AE research but comparisons are hard because there are no standardized definitions. 29 Therefore, the International Eczema Council and Eli Lilly and Company have worked on a validated five-point Investigator Global Assessment (IGA) scale, which was incorporated in to the core dataset for this item. 30, 31 Patient global assessment
Little research has been done towards the patient global assessment (PGA). This subdomain of the long-term control domain has been discussed during HOME V, but as yet stays undefined. 17 However, as we decided to use the five-point IGA scale, the five-point PGA for the item 'patient global assessment' was chosen.
Skin-specific quality-of-life score
For this item, during the HOME IV (adults) and HOME V (children) meetings it was concluded that there is currently no measurement instrument that can be recommended. 16, 17, 19, 20 Considering feasibility and the most commonly used instruments, it was decided to use the Dermatology Life Quality Index (DLQI), the Children's DLQI (CDLQI) and the Infants' Dermatitis Quality of Life Index (IDQoL). Further validation work on the DLQI was recently published by Patel et al. 32 Generic quality-of-life score
Feasibility, access to different languages and the high degree of usage were the main reasons to choose the EQ-5D-5L (adults) and the EQ-5D-Y (children) as the preferred measurement instruments for this item.
Patient-reported satisfaction with atopic eczema care received, impact of atopic eczema on the family and adherence to treatment between appointments
We recommend the use of an adapted Psoriasis Satisfaction questionnaire (PsoSat), a questionnaire that measures the treatment satisfaction in patients with psoriasis, 33 the Family Dermatology Life Quality Index 34 and the Medication Adherence Report Scale (MARS), which was originally developed for the adherence with oral medication in asthma but can be easily adapted for patients with AE. 35 The MARS will be optional until it is validated for AE.
When to measure
Thirteen of 16 participants (81%) completed the survey. Eight of 13 (62%) voted for a minimum follow-up frequency of every 3 months while on therapy; seven of 13 participants (54%) voted for an extra visit 4 weeks after baseline. Seven of 13 participants (54%) voted for a minimum follow-up frequency of every 6 months while off treatment. The recommended visit window for patients both on and off therapy was set at +/À 1 month (58% and 50%). An overview is shown in Table 2 .
Discussion
This consensus study identified measurement instruments for all domain items previously agreed on during our Delphi study for AE research registries that capture data on adults and children with moderate-to-severe AE on phototherapy and systemic immunomodulatory therapy. By doing so, a complete core dataset is now available for usage by researchers worldwide.
Our recommendations for core domains and domain items for data collection were based on a carefully conducted international Delphi process, in which over 400 stakeholders (physicians, nurses, patients, methodologists, regulatory body and industry representatives) from over 30 countries contributed. 11, 12 The results of this Delphi directly fed into the 'how to measure' recommendations presented here. 12 In addition, proposals for the measurement instruments were based on the recommendations from the HOME initiative. Although primarily meant for clinical trials and not specifically for research registries, the HOME recommendations represent an international consensus on core outcomes based on validation studies and systematic reviews. The experts who participated in the HOME initiative participated in this study as well, allowing us to benefit from their expertise. Further, a patient and experts in the field of AE and/or AE measurement instruments were involved, which strengthened our recommendations and provided insight into important aspects that will play a role during implementation of the core dataset.
As for potential limitations, the final decisions on the 'how to measure' were made by a relatively small group for feasibility reasons, which did not include representatives from the regulatory bodies or pharmaceutical industry. However, where required expertise was not available within the group, external experts were consulted. In addition, because observational studies need large numbers of patients, this core dataset will need to be implemented in many research facilities. Although this might prove to be a challenge, we think that, as many of the items from the core dataset are already registered in clinical practice, this will not become a problem. Although we had a very experienced patient representative, who also was the Chair of the Dutch Association for People with Atopic Dermatitis, it would have been desirable to include more patient representatives in this consensus process. Finally, for a number of domain items no underlying systematic reviews of the evidence were available. This meant that, in this study, expert opinion played a larger role than, for example, in the HOME initiative.
As a next step, the feasibility of the core dataset and the proposed follow-up frequencies need to be tested. As part of such feasibility work, it is important to keep in mind that our recommendations apply to research registries, rather than record keeping in routine clinical practice. We are also Table 2 When to measure the domain items for national atopic eczema treatment registries
Category
When to measure Follow-up frequency while on therapy 4 weeks, 3 months and then every 3 months Follow-up frequency while off therapy Every 6 months Visit window +/À1 month encouraged that the larger TREATgermany dataset appears feasible to local investigators in its current form. 21 This core dataset will allow the international dermatology community to generate, compare and pool data of patients with AE on phototherapy and systemic therapy across country borders to answer important questions on long-term effectiveness, safety and cost-effectiveness of these therapies; which can only be addressed with very large patient numbers (e.g. on rare adverse events). We are working on a standardized data collection/storage platform to facilitate uniform data collection, pooling and analyses. In the long-term, we hope that our recommendations and the analyses generated by national treatment registries will complement the more short-term results from randomized controlled trials and ultimately aid the standardization and optimization of patient management.
As the uptake of this core dataset by new national AE registries is vital, we encourage colleagues to contact us through our website (https://treat-registry-taskforce.org), to extend this collaborative project not just within Europe but also beyond.
